Loading
A phase 1/2 trial of Dostarlimab, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by iOnctura, active and no longer recruiting.
A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients is a phase 1/2 interventional study registered as NCT06879717 by iOnctura, with 45 participants planned, started 2025-04-22 and due to reach its primary completion in 2027-01. Interventions recorded: roginolisib, Dostarlimab, Docetaxel. Conditions listed: Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Roginolisib, iOnctura.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Immune checkpoint inhibitors.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Immune checkpoint inhibitors.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Docetaxel, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/